According to relevant media reports, ShineyoMedical, a provider focused on cardiac electrophysiology and peripheral vascular interventional treatment solutions, recently announced the completion ofNearly 100 Million Yuan in Series A+ RoundFinancing, this round of financing was led byGuangzhou Jinkong Fund led the investment, with participation from Zhuopu Capital and Jinxin CapitalAndZhangjiagang Industrial Capitaland other investment institutions jointly participated, existing shareholdersXingzheng CapitalContinuous Support.

This round of funding will be mainly used for the construction of the company's commercialization team, acceleration of production base operations, and R&D of product pipelines, creating a differentiated design matrix of cardiac electrophysiology and peripheral vascular intervention products.

ShineyoMedical was established in May 2020 in the Zhangjiang High-Tech Zone of the China (Shanghai) Pilot Free Trade Zone. Relying on three major technology development platforms—active devices, interventional catheters, and biomaterials—the company has entered two key fields: cardiac electrophysiology and peripheral interventions. It aims to become a leading innovator in the field of electrophysiology and minimally invasive peripheral vascular interventional medical devices, providing doctors and patients with cutting-edge, affordable, and innovative clinical solutions.

Since its establishment 4 years ago, ShineyoMedical has independently developed innovative products in cardiac electrophysiology and peripheral vascular intervention, such as the cardiac pulsed field ablation system (PFA) and venous closure system.The registration applications for related products were officially accepted by the NMPA in the first half of 2024 and are expected to enter the commercial validation phase by the end of 2024.

In April 2024, VariSeal, a product independently developed by ShineyoMedical^®ShineyoMedical's Vein Closure System Wins Second Prize in VINNOVA's 2nd Innovation Competition.

ShineyoMedical's Self-developed VariSeal^®ShineyoMedical's Venous Closure System Wins Second Prize in VINNOVA's 2nd Innovation Competition

VariSeal^®The Venous Closure System is an innovative therapy for varicose vein treatment.Composed of an adhesive and a delivery system. The adhesive solidifies from liquid upon contact with anions in the human body via an anionic polymerization mechanism, achieving vascular adhesion; the delivery system consists of a dispensing gun and an injection catheter. With the cooperation of a guidewire and a long sheath, the injection path is established. Guided by both the injection catheter and red light, the adhesive is injected into the target vessel location.

Particularly impressive is the system's unique red light design, where the visible red light on the body surface acts as a "guiding light" during surgery, providing the surgeon with intuitive and clear navigation. The design of the dispensing gun is equally ingenious, capable of achieving precise micro-injections as small as 0.1ml. The combination of fiber optic navigation and precise injection can effectively achieve the clinical goal of accurately sealing superficial veins in the lower limbs.

Currently, VariSeal^®The venous closure system product has successfully completed clinical trial follow-ups, and the registration materials have been submitted.

VariSeal^®Venous Closure System

Rhythpulse^®Multi-Channel Cardiac Pulsed Field Ablation SystemIs another flagship product of ShineyoMedical, which entered the NMPA Innovative Medical Device Special Review in March 2023. The product consists of a multi-channel cardiac pulsed electric field ablation system and a cardiac pulsed ablation catheter, and is compatible with mainstream 3D cardiac electrophysiological mapping systems. It is mainly used for the treatment of tachyarrhythmia by precisely delivering high-voltage pulses to myocardial tissue, causing irreversible electroporation of cardiomyocytes within the target area, thereby permanently isolating abnormal electrical signal conduction and restoring normal sinus rhythm to achieve therapeutic purposes.

ShineyoMedical's multi-channel pulsed electric field ablation instrument can release pulse energy individually or in combination, and is equipped with an electrocardiogram gating function, which can sense the refractory period for discharge to avoid ventricular fibrillation. The discharge modes during treatment are diverse, enabling precise ablation of the target area.

At the same time, the specifications of the cardiac pulsed field ablation catheter can cover the full-size pulmonary vein vestibule area. The unique small loop diameter (10mm) catheter enables localized large focal contact ablation; the proprietary patented asymmetrical ablation electrode design improves ablation efficiency, reduces ineffective discharge of electrodes in the blood, avoids hemolysis-related renal function damage, and achieves targeted ablation effects.

Currently, the product has completed clinical enrollment trials and a one-year follow-up, and submitted registration materials in the first half of the year.

Rhythpulse^®Multi-channel Cardiac Pulsed Field Ablation System

For obtaining this round of financing,ShineyoMedical Founder Chen ShuguoStated: We are grateful for the support and recognition from this round of investment institutions and existing shareholders. This round of financing occurs as we are in the process of submitting multiple products for registration and commencing commercial operations. It is a great honor to receive investors' backing amidst the current capital winter. The ShineyoMedical team will continue to work tirelessly, accelerating the market launch of our products to benefit more patients as soon as possible.

Nie Huiming, Head of Biomedical Investment at Guangzhou Jinkong FundThe investment institutions representing this round of investment stated: The founding team of ShineyoMedical has a diverse background and can accurately grasp the industry development trends and changes in the cardiovascular field. In addition, the general technology platform of ShineyoMedical can continuously innovate in product design concepts, enrich the product portfolio, and achieve commercialization. We are optimistic about the founding team, technical reserves, and product layout of ShineyoMedical, and believe that ShineyoMedical will continue to lead the industry with its technological innovation capabilities, benefiting a large number of patients. Guangzhou Golden Control Fund will firmly support the development of the biopharmaceutical industry and the process of innovative medical product research, development, and market launch.

Guangzhou Financial Holdings Group Co., Ltd. is a state-owned financial holding platform established by the Guangzhou Municipal Committee and the Guangzhou Municipal Government to consolidate municipal financial assets. It has become the largest local financial holding group in China in terms of asset scale, with the highest credit rating and the most complete set of financial licenses. It serves as an important booster for achieving high-quality economic development in Guangzhou. As of the end of June 2023, the group's total assets amounted to 881.864 billion yuan, with international ratings of A- from Fitch and BBB+ from Standard & Poor's, representing the highest credit rating among local financial holding groups in China. It ranked 258th in the 2023 Top 500 Service Enterprises in China.

Suzhou Zhuopu Investment Fund Management Co., Ltd. was established in 2018 as a wholly-owned subsidiary of Suzhou Asset Management Co., Ltd. It has long focused on fields such as next-generation information technology, aerospace, semiconductors, biomedicine, and artificial intelligence, with a management scale exceeding 2 billion yuan. Zhuopu Capital actively manages several direct investment funds, including Zhuopu No. 1 Fund, Gusu Talent Phase II Fund, Zhangjiagang Talent No. 1 Fund, Zhuopu Yongying Fund, and Zhuoyun Qihang Fund, with a primary focus on the four leading industries of Suzhou: electronic information, high-end equipment, advanced materials, and new energy.

Xingzheng Innovation Capital Management Co., Ltd., established in 2010, is a wholly-owned private equity investment fund subsidiary of Xingye Securities Co., Ltd. (SH601377), with a cumulative total scale of managed and serviced funds exceeding tens of billions of yuan. Xingzheng Capital is committed to combining its own equity investment experience with the platform advantages of a securities firm subsidiary to provide multi-faceted post-investment value-added services for invested enterprises, growing healthily and continuously developing together with the invested enterprises, progressing from excellence to eminence.

Zhangjiagang Shazhou Sci-Tech Innovation Fund, jointly established by the Zhangjiagang Science and Technology Bureau and Zhangjiagang Innovative Investment Group, adopts a direct investment strategy. It focuses on emerging industrial chain projects such as specialty semiconductors, biomedicine and high-end medical devices, new energy, and the digital economy. Among these, healthcare and high-end medical devices are also key areas of focus for the fund. By attracting a group of potentially high-quality projects with advanced industrialization, strong market recognition, and high technological content, the fund aims to bring "fresh momentum" to the industrial development of Zhangjiagang City and promote industrial transformation and upgrading.

Zhangjiagang Jinxin Capital Investment Management Co., Ltd. is a wholly state-owned company依托于 Jiangsu Yangtze River International Metallurgical Industry Park, mainly engaged in equity investment and investment management. Jinxin Capital focuses on the development of the park's "3+N" industrial cluster, creating an information window for the park’s industrial capital. It actively plays a role in capital allocation, flexibly uses various investment methods to guide social capital investment into the park’s industries, promotes internal and external capital flow, attracts and supplements resources, and uses investment to drive guidance. It advances the park’s industrial chain by enhancing, supplementing, extending, and strengthening it, adopting a strategy of "bringing in and going global," and leading state-owned capital and enterprises in the park toward broader horizons.